Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1947 1
1949 1
1950 1
1953 4
1955 3
1958 1
1961 3
1962 3
1963 3
1964 7
1965 19
1966 23
1967 53
1968 65
1969 98
1970 112
1971 179
1972 263
1973 280
1974 319
1975 350
1976 268
1977 253
1978 230
1979 216
1980 211
1981 212
1982 295
1983 254
1984 361
1985 441
1986 385
1987 419
1988 319
1989 401
1990 365
1991 382
1992 412
1993 394
1994 321
1995 354
1996 370
1997 364
1998 348
1999 375
2000 369
2001 339
2002 375
2003 342
2004 360
2005 343
2006 364
2007 353
2008 386
2009 403
2010 449
2011 424
2012 464
2013 468
2014 499
2015 513
2016 470
2017 504
2018 554
2019 530
2020 575
2021 556
2022 524
2023 459
2024 124

Text availability

Article attribute

Article type

Publication date

Search Results

19,245 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis and treatment of therapy-related acute myeloid leukemia.
Strickland SA, Vey N. Strickland SA, et al. Crit Rev Oncol Hematol. 2022 Mar;171:103607. doi: 10.1016/j.critrevonc.2022.103607. Epub 2022 Jan 31. Crit Rev Oncol Hematol. 2022. PMID: 35101585 Free article. Review.
In patients deemed fit, t-AML treatment can involve CPX-351 (liposomal daunorubicin and cytarabine) or conventional chemotherapy, ideally followed by hematopoietic cell transplantation. ...
In patients deemed fit, t-AML treatment can involve CPX-351 (liposomal daunorubicin and cytarabine) or conventional chemotherapy, ide …
[Ara-C].
Onozawa M, Teshima T. Onozawa M, et al. Nihon Rinsho. 2015 Feb;73 Suppl 2:623-7. Nihon Rinsho. 2015. PMID: 25831835 Japanese. No abstract available.
Antimetabolites.
Capizzi RL, White JC, Fernandes DJ. Capizzi RL, et al. Baillieres Clin Haematol. 1991 Jan;4(1):15-45. doi: 10.1016/s0950-3536(05)80283-5. Baillieres Clin Haematol. 1991. PMID: 2039856 Review. No abstract available.
Cytarabine and neurologic toxicity.
Baker WJ, Royer GL Jr, Weiss RB. Baker WJ, et al. J Clin Oncol. 1991 Apr;9(4):679-93. doi: 10.1200/JCO.1991.9.4.679. J Clin Oncol. 1991. PMID: 1648599 Review.
Cytarabine is an effective drug in the treatment of certain hematologic malignancies and its common toxicities are myelosuppression and gastrointestinal disturbance. In the past decade, neurotoxicity has been an increasingly recognized cytarabine effect. Intrathecal
Cytarabine is an effective drug in the treatment of certain hematologic malignancies and its common toxicities are myelosuppression a
Cytarabine.
Betcher DL, Burnham N. Betcher DL, et al. J Pediatr Oncol Nurs. 1990 Oct;7(4):154-7. doi: 10.1177/104345429000700406. J Pediatr Oncol Nurs. 1990. PMID: 2081008
Cytarabine is effective in the treatment of leukemias and CNS disease when given SQ, IM, IV, or intrathecally. Research is continuing to investigate high-dose therapy with cytarabine....
Cytarabine is effective in the treatment of leukemias and CNS disease when given SQ, IM, IV, or intrathecally. Research is continuing
[Cytarabine].
Ota K. Ota K. Gan To Kagaku Ryoho. 1987 Oct;14(10):2983-7. Gan To Kagaku Ryoho. 1987. PMID: 3478003 Japanese.
Cytarabine (ara-C) is the first line agent with its excellent activity for acute myelogenous leukemia. ...
Cytarabine (ara-C) is the first line agent with its excellent activity for acute myelogenous leukemia. ...
Cytarabine (Cytosar).
[No authors listed] [No authors listed] Clin Pharmacol Ther. 1970 Jan-Feb;11(1):155-60. doi: 10.1002/cpt1970111155. Clin Pharmacol Ther. 1970. PMID: 5262667 No abstract available.
Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations.
Shabashvili DE, Feng Y, Kaur P, Venugopal K, Guryanova OA. Shabashvili DE, et al. Exp Hematol. 2022 Jun;110:20-27. doi: 10.1016/j.exphem.2022.03.008. Epub 2022 Mar 16. Exp Hematol. 2022. PMID: 35306047 Free PMC article. Review.
Cytarabine and other chain-terminating nucleoside analogs that damage replication forks in rapidly proliferating cells are a cornerstone of leukemia chemotherapy, yet the outcomes remain unsatisfactory because of resistance and toxicity. ...In this article, we first overvi
Cytarabine and other chain-terminating nucleoside analogs that damage replication forks in rapidly proliferating cells are a cornerst
ARA-C analogs.
Alberto P. Alberto P. Antibiot Chemother (1971). 1978;23:88-98. doi: 10.1159/000401475. Antibiot Chemother (1971). 1978. PMID: 348088 Review.
Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia.
Keane N, Freeman C, Swords R, Giles FJ. Keane N, et al. Expert Rev Hematol. 2013 Feb;6(1):9-24. doi: 10.1586/ehm.12.68. Expert Rev Hematol. 2013. PMID: 23373775 Review.
Cytosine arabinoside (cytarabine or Ara-C) has been one of the cornerstones of treatment of acute myeloid leukemia since its approval in 1969. ...
Cytosine arabinoside (cytarabine or Ara-C) has been one of the cornerstones of treatment of acute myeloid leukemia since its approval …
19,245 results
You have reached the last available page of results. Please see the User Guide for more information.